ESMO 2021 Jazz Pharmaceuticals AML symposium - European Medical Journal

ESMO 2021 Jazz Pharmaceuticals AML symposium

Hematology

Insight beyond Phase 3: Does real-world evidence impact how we treat high-risk AML

High-risk AML defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia related changes (AML-MRC).

Chair: Prof Hartmut Döhner

This is a promotional symposium for healthcare professionals only.

Prescribing information and adverse event reporting details will be available during the sessions of the symposium

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now